Piramal Pharma

Amendment to the Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information

09 Sep, 2025 | 06:52pm • Source: BSE

Intimation of Schedule of Analyst/ Institutional Investor Meeting under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

02 Sep, 2025 | 03:44pm • Source: BSE

Sustainability Report of Piramal Pharma Limited for the Financial Year 2024-25.

25 Aug, 2025 | 04:16pm • Source: BSE

Press Release- Piramal Pharma Solutions (''"PPS") and NewAmsterdam Pharma invest in dedicated suite to enhance Oral Solid Dosage capabilities at PPS'' Sellersville , Pennsylvania site

21 Aug, 2025 | 04:55pm • Source: BSE

Please refer attachment

20 Aug, 2025 | 09:07pm • Source: BSE

Intimation of Schedule of Analyst/ Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

20 Aug, 2025 | 06:03pm • Source: BSE

Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015- Fire occurrence at a third-party warehouse utilized by Company

07 Aug, 2025 | 06:49pm • Source: BSE

Intimation of Schedule of Analyst/ Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

04 Aug, 2025 | 03:19pm • Source: BSE

Transcript of Conference Call on the Unaudited Financial Results (Standalone and Consolidated) for the quarter ended 30th June, 2025

31 Jul, 2025 | 02:04pm • Source: BSE

Proceedings and Voting Results of the 5th AGM of the Company

30 Jul, 2025 | 09:19pm • Source: BSE

Audio Recording of Conference Call on the Unaudited Financial Results (Standalone and Consolidated) for the quarter ended 30th June, 2025

29 Jul, 2025 | 12:28pm • Source: BSE

Please refer attachment

28 Jul, 2025 | 09:59pm • Source: BSE

Investor Presentation - Unaudited Financial Results (Standalone & Consolidated) of the Company for the quarter ended 30th June, 2025

28 Jul, 2025 | 09:49pm • Source: BSE

Press release and Investor Presentation - Unaudited Financial Results (Standalone & Consolidated) of the Company for the quarter ended 30th June, 2025

28 Jul, 2025 | 09:46pm • Source: BSE

Please refer attachment

28 Jul, 2025 | 09:33pm • Source: BSE

Grant of Stock Options pursuant to Piramal Pharma Limited - Employee Stock Option and Incentive Plan 2022

28 Jul, 2025 | 05:30pm • Source: BSE

Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Credit Rating

21 Jul, 2025 | 12:33pm • Source: BSE

Intimation of Conference Call with Investors/Analysts under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

18 Jul, 2025 | 02:16pm • Source: BSE

Piramal Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/07/2025 ,inter alia, to consider and...

18 Jul, 2025 | 02:05pm • Source: BSE

Disclosure under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ( SEBI Listing Regulations ) ESG Rating

10 Jul, 2025 | 12:11pm • Source: NSE